436093-16-2 Usage
Uses
Used in Pharmaceutical Industry:
1-(4-Fluorobenzoyl)piperidine-3-carboxylic acid is used as a key intermediate in the synthesis of various pharmaceutical drugs and research compounds. Its unique structural features allow for the development of new drug candidates and bioactive molecules, contributing to the advancement of pharmaceutical research and drug discovery.
Used in Drug Design and Development:
As a valuable building block, 1-(4-Fluorobenzoyl)piperidine-3-carboxylic acid is used in drug design and development to create novel compounds with potential therapeutic effects. Its structural versatility enables researchers to explore various modifications and combinations, leading to the discovery of new drugs with improved efficacy and safety profiles.
Used in Research and Development:
1-(4-Fluorobenzoyl)piperidine-3-carboxylic acid is also used in research and development for the study of its potential therapeutic effects. Further investigation into its pharmacological properties can provide valuable insights into its potential applications in the treatment of various diseases and conditions, ultimately contributing to the development of innovative therapeutic strategies.
Check Digit Verification of cas no
The CAS Registry Mumber 436093-16-2 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 4,3,6,0,9 and 3 respectively; the second part has 2 digits, 1 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 436093-16:
(8*4)+(7*3)+(6*6)+(5*0)+(4*9)+(3*3)+(2*1)+(1*6)=142
142 % 10 = 2
So 436093-16-2 is a valid CAS Registry Number.
436093-16-2Relevant academic research and scientific papers
TRICYCLIC COMPOUNDS AS GLUTAMATE RECEPTOR MODULATORS
-
Page/Page column 76, (2010/05/14)
Disclosed herein are compounds that may be negative allosteric modulators of metabotropic receptors-subtype 5, and methods of making and using same.
ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS
-
Page/Page column 52-53, (2008/06/13)
The present invention relates to new compounds of formula (I) wherein A, B, P, Q, W, Rl and R2 are defined in the description; invention compounds are useful in the prevention or treatment of central nervous system disorders as well as other disorders modulated by mGluR5 receptors.
